Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.70217
Abstract: This study aimed to evaluate the efficacy and safety of atezolizumab combined with bevacizumab (Atez/Bev) compared to lenvatinib (LEN) as first‐line systemic therapy for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma… read more here.
Keywords: atezolizumab; stage hepatocellular; exceeding seven; hepatocellular carcinoma ... See more keywords
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.936
Abstract: Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options,… read more here.
Keywords: phase; cell lung; atezolizumab; every weeks ... See more keywords
A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-019-01441-3
Abstract: Purpose The use of antibodies as tracers requires labeling with isotopes with long half-lives due to their slow pharmacokinetics, which creates prohibitively high radiation dose to non-target organs. Pretargeted methodology could avoid the high radiation… read more here.
Keywords: 99m hynic; hynic peg; chemistry; atezolizumab ... See more keywords
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01295-y
Abstract: Atezolizumab (Tecentriq ® ), an immune checkpoint inhibitor against programmed death ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination with nab-paclitaxel) in the USA, the EU (as first-line)… read more here.
Keywords: nab paclitaxel; combination nab; advanced triple; plus nab ... See more keywords
Bladder cancer: Atezolizumab: an alternative to cisplatin?
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2016.271
Abstract: Cisplatin-based chemotherapy is an effective first-line treatment of patients with locally advanced or metastatic urothelial carcinoma; however, many patients are ineligible to receive cisplatin, and other types of chemotherapy, although better tolerated, are not as… read more here.
Keywords: alternative cisplatin; trial; treatment; cisplatin ... See more keywords
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Cancer"
DOI: 10.1038/s41416-024-02776-7
Abstract: Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC). After identifying the recommended dose, patients with… read more here.
Keywords: atezolizumab; advanced gynaecological; combination; triple negative ... See more keywords
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-93113-y
Abstract: Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on… read more here.
Keywords: cxcr3; response; atezolizumab; cell priming ... See more keywords
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13127
Abstract: Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti-drug antibodies (ADA) on the PK of… read more here.
Keywords: immunogenicity; ada; exposure; pharmacology ... See more keywords
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Open"
DOI: 10.1136/bmjopen-2024-096617
Abstract: Background Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade of the T-cell immunoreceptor with immunoglobulin… read more here.
Keywords: atezolizumab; treatment; trial; chemotherapy ... See more keywords
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-3488
Abstract: Purpose: Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and activity of atezolizumab, along… read more here.
Keywords: response; clinical activity; activity; atezolizumab ... See more keywords
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0298
Abstract: The assertion of Goldstein and colleagues that lower or less frequent atezolizumab dosingmay be therapeutically effective is based onmean steady-state drug concentration data. However, a general consideration in determining the recommended dose is to ensure… read more here.
Keywords: response; activity; majority patients; atezolizumab ... See more keywords